This promotional content has been developed, organised, and funded by Pfizer Ltd and is intended for qualified UK healthcare professionals only.
XELJANZ® (tofacitinib citrate) and MAXTREX® (methotrexate) Prescribing Information is available here
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
To find out more about Xeljanz, visit PfizerPro here.
The Role of Xeljanz (tofacitinib citrate) in Rheumatology: A Clinician Perspective
Zoe Cole, Consultant Rheumatologist and Associate Medical Director, Salisbury District Hospital, UK, discusses her experience with Xeljanz in rheumatology.
Prescribing Information: https://www.pfizerpiindex.co.uk/xeljanz-maxtrex
Spotlight on Xeljanz (tofacitinib citrate) in RA: A Review of Efficacy and Safety from Real-World Evidence
Hear from Patrick Kiely, Consultant Rheumatologist, St. Georges University Hospital, London, UK, discussing the real-world evidence data for Xeljanz.
Prescribing Information: https://www.pfizerpiindex.co.uk/xeljanz-enbrel-inflectra-maxtrex-ruxience
Juvenile Idiopathic Arthritis: A Clinician Perspective
Hear Athimalaipet V Ramanan, Consultant Paediatric Rheumatologist, Bristol Royal Hospital for Children, UK, give his perspective on juvenile idiopathic arthritis (JIA).
Prescribing Information: https://www.pfizerpiindex.co.uk/xeljanz
GRAPPA Treatment Recommendations: 2021 Updates
Watch the video infographic where you can watch Laura Coates, Co-lead of the GRAPPA Recommendations and Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK, and the GRAPPA group investigators explain the GRAPPA Treatment recommendations for psoriatic arthritis.
Prescribing Information: https://www.pfizerpiindex.co.uk/xeljanz
Updated Regulatory Guidance on JAK Inhibitors – An Expert Rheumatologist’s Perspective
Expert rheumatologist, James Galloway, Reader and Honorary Consultant Rheumatologist, King’s College London, UK, gives his perspective on the updated regulatory guidance on JAK inhibitors.
Prescribing Information: https://www.pfizerpiindex.co.uk/xeljanz-maxtrex
To find out more, or to watch more videos from our experts, please visit PfizerPro here.
PP-XEL-GBR-4709 | October 2023
